Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.

doi:10.1093/cid/ciy801

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 17 May 2019

Evans Scott R, Tran Thuy Tien T, Hujer Andrea M, Hill Carol B, Hujer Kristine M, Mediavilla Jose R, Manca Claudia, Domitrovic T Nicholas, Perez Federico, Farmer Michael, Pitzer Kelsey M, Wilson Brigid M, Kreiswirth Barry N, Patel Robin, Jacobs Michael R, Chen Liang, Fowler Vance G, Chambers Henry F, Bonomo Robert A

Abstract excerpt

BACKGROUND: Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa. METHODS: In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azabicyclo Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Lactam Resistance

Share to beta-Lactamase Inhibitors

Share to Ceftazidime

Share to Cephalosporins

Share to Drug Combinations

Share to Molecular Diagnostic Techniques

Share to Pseudomonas Infections

Source

Open in PubMed Open full text

Identifiers

PMID: 30239599
DOI: 10.1093/cid/ciy801
PMCID: PMC6938201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.PMID 30239599Read ↗

Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance MechanismsSemantic proximity Read ↗

Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.Semantic proximity Read ↗

Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactamSemantic proximity Read ↗

Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and IISemantic proximity Read ↗

Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021Semantic proximity Read ↗

Molecular diagnostics for genotypic detection of antibiotic resistance: current landscape and future directionsSemantic proximity Read ↗

Fighting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with machine learning-enabled molecular diagnosticsSemantic proximity Read ↗

Keeping up with the pathogens: improved antimicrobial resistance detection and prediction from Pseudomonas aeruginosa genomes.Semantic proximity Read ↗

Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countriesSemantic proximity Read ↗

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance studySemantic proximity Read ↗

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosaSemantic proximity Read ↗

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.